Home › Funds › Eversept Partners, LP › MRNA
Eversept Partners, LP position in MRNA
MODERNA INC · Health Care
Eversept Partners, LP reported holding 152,122 shares of MRNA (MODERNA INC) in its Q2 2026 13F filing — a position valued at US$10.7M, representing 0.56% of its reported portfolio and ranking #45 among its reported holdings. Eversept Partners, LP has disclosed MRNA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Eversept Partners, LP's MRNA position evolved
Eversept Partners, LP first disclosed a stake in MRNA in Q4 2025 at 267,823 shares (US$7.9M). The position peaked in Q2 2026 at 152,122 shares, worth US$10.7M. Across 3 filings, Eversept Partners, LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 152,122 shares valued at US$10.7M — a reduction of -7,586 shares quarter over quarter.. Notable position changes include a 40% trim in Q1 2026 (shares rose 38% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 267.82K | $7.90M | New |
| Q1 2026 | 159.71K | $8.11M | Reduce |
| Q2 2026 | 152.12K | $10.65M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MRNA and 13F data
MRNA (MODERNA INC) is a Health Care company. 37 other funds we track also report a position in MRNA — the largest reported positions include Baillie Gifford & Co (US$1.28B), Theleme Partners LLP (US$564.3M), BANQUE PICTET & CIE SA (US$414.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MRNA
- Baillie Gifford & Co 18.21M sh · $1.28B · Q2 2026
- Theleme Partners LLP 8.06M sh · $564.27M · Q2 2026
- BANQUE PICTET & CIE SA 2.15M sh · $414.27M · Q3 2026
- Flagship Pioneering, LLC 4.63M sh · $324.39M · Q2 2026
- Douglas Lane & Associates, LLC 1.16M sh · $223.56M · Q3 2026
- Beau Ventures, LLc 1.00M sh · $192.58M · Q3 2026
- Merck & Co., Inc. 2.31M sh · $161.64M · Q2 2026
- Baron Funds 1.99M sh · $139.32M · Q2 2026
- BAMCO INC /NY/ 1.99M sh · $139.32M · Q2 2026
- IMC-Chicago, LLC 1.70M sh · $119.21M · Q2 2026
More on Eversept Partners, LP
FAQ
How long has Eversept Partners, LP held MRNA?
Eversept Partners, LP has disclosed MRNA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Eversept Partners, LP's current position in MRNA?
As of Q2 2026, Eversept Partners, LP holds 152.12K shares of MRNA (MODERNA INC), valued at $10.65M, representing 0.56% of its reported portfolio and ranking #45.
Has Eversept Partners, LP been buying or selling MRNA?
In the latest 13F filing (Q2 2026), Eversept Partners, LP reduced its position in MRNA. The position peaked in Q2 2026 at 152.12K shares.
Which other funds hold MRNA?
Other major institutional holders of MRNA include Baillie Gifford & Co, Theleme Partners LLP, BANQUE PICTET & CIE SA, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.